ɬÀï·¬

Annual Meeting

Cracking foods’ anti-cancer properties

Intrigued first by tamarind’s antibacterial ability, researcher in Puerto Rico next sets her sights on legumes as she investigates ways to defeat triple-negative inflammatory breast cancer

What if patients with breast cancer could consume legumes, such as soy sprouts, and greatly reduce the chances of their cancer metastasizing? This is one of the questions researchers at the University of Puerto Rico at Río Piedras are interested in answering, and their work already has yielded some intriguing findings, which will be presented Tuesday in Philadelphia at the annual meeting of the ɬÀï·¬. 

Courtesy of Keishla M. Rodríguez–Mártir
Keishla M. Rodríguez–Mártir works with her cancer cell lines.

Graduate student Keishla M. Rodríguez–Mártir is working on her dissertation in the . Rodríguez–Mártir is studying , a phytoestrogen similar in structure to estrogen and found in foods such as soy, alfalfa, clover and Kala chala (a type of chickpea), among others. She aims to determine if coumestrol has anti-cancer effects in , or TN-IBC, cell lines as it does in other cancer cell lines. 

Rodríguez–Mártir’s dissertation research idea sprang from a project she was involved in as an undergraduate student at the University of Puerto Rico at Aguadilla, where she was assessing tamarind’s antibacterial properties. 

“(This property) always called my attention — how something that we can buy at the grocery store works against bacterial infections,” she said. “This was something I was interested in exploring. (I wondered if) people receiving chemotherapy could supplement their treatment with something natural and accessible to them.” 

Triple-negative breast cancer does not have estrogen or progesterone receptors, and it has low-to-no HER2 protein production. As a result, it cannot be treated with hormone or HER2-targeted therapy. 

Molecular structure of coumestrol, a phytoestrogen with a structure similar to estrogen.

The inflammatory aspect of TN-IBC further complicates clinical outcomes, because it does not present with lumps but instead creates redness and inflammation and thus may not show up on a mammogram. This presentation causes doctors to explore other possible noncancerous causes first, which ultimately delays cancer detection. By the time it is diagnosed, it usually has metastasized and consequently results in a worse prognosis for the patient. 

Rodríguez–Mártir dived into the scientific literature and came upon studies of phytoestrogens and their relationship to in women with breast cancer. Specifically, she focused on coumestrol because suggest that it has cytotoxic effects against triple-negative cell lines, but it had not been studied yet in the context of triple-negative inflammatory breast cancer. 

Rodríguez–Mártir first sought to test the hypothesis that coumestrol could have cytotoxic effects on TN-IBC cell lines by using a 2D cell-culture model of TN-IBC cells. She conducted dose-response assays with coumestrol to determine half-maximal inhibitory concentration, followed by cell viability, migration and invasion assays, complemented by assessment of downstream signaling following coumestrol treatment. 

She determined that coumestrol decreases cell viability, migration and invasion in TN-IBC cell lines. She also demonstrated that coumestrol downregulates pro-oncogenic signaling and upregulates genes involved in breast cancer suppression. 

“Studies have determined that Asian and vegetarian women with high phytoestrogen dietary consumption have a low rate of incidence of breast cancer. Further, Chinese women who have breast cancer and consume phytoestrogens have a significantly lower mortality rate than their counterparts who do not,” she said. “I would like to identify a natural compound that (patients) can easily consume to support their therapy.” 

Keishla M. Rodríguez–Mártir will present this research at 1:10 p.m. Tuesday, April 5, in Exhibit/Poster Hall A–B, Pennsylvania Convention Center (Poster Board Number A310) (). In addition, the next step in her project, 3D models using matrigels, will be presented at the same time by her undergraduate colleague Ayeisha Colón–Ortíz ().

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
O. Hecmarie  Meléndez-Fernández

O. Hecmarie Meléndez-Fernández is a Ph.D. candidate in neuroscience at West Virginia University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬÀï·¬ paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ɬÀï·¬ paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.